This post is for consultant pharmacists, clinical pharmacy directors, and the skilled nursing facility (SNF) leaders who evaluate their pharmacy oversight program. You will get a plain-language walkthrough of what CMS Phase 3 pharmacy requirements mean for medication regimen review (MRR), gradual dose reduction (GDR) support, psychotropic monitoring, and the documentation that survives survey. Regulations and clinical criteria change, so treat this as general education and confirm current rules against the official sources linked below.
What CMS Phase 3 changed for pharmacy oversight
The CMS Requirements of Participation for long-term care facilities rolled out in three phases, and Phase 3 tightened the expectations around systems that support resident safety. For pharmacy, the practical effect is that ad hoc chart review and a monthly signature are no longer enough. Surveyors increasingly want to see a defined, consistent process that connects clinical findings to facility action.
Two areas draw the most attention. First, the pharmacy services and medication regimen review requirements expect a licensed pharmacist to review each resident's regimen and to report irregularities to the attending physician and the director of nursing (DON). Second, the unnecessary-drug and psychotropic provisions expect the facility to justify continued use of certain medications, document rationale, and pursue reduction when clinically appropriate.
Because F-tag numbers and citation language are periodically updated, verify the exact current tags and requirements in the CMS State Operations Manual and the regulations at eCFR and CMS.gov rather than relying on a number you saw in an older policy.
The core pharmacist responsibilities under Phase 3
Phase 3 does not replace the consultant pharmacist's clinical judgment — it raises the bar for how that judgment is captured and acted on. The recurring obligations you should be able to demonstrate include the following.
- Medication regimen review for every resident. A licensed pharmacist evaluates each resident's medications on the required cadence and identifies irregularities, including potentially inappropriate medications, duplications, and monitoring gaps.
- Irregularity reporting and closure. Findings are communicated in writing to the attending physician and the DON, and the facility documents the response — accepted, rejected with rationale, or deferred with a plan.
- Unnecessary-drug review. The pharmacist evaluates whether a drug is used without adequate indication, in excessive duration or dose, without adequate monitoring, or in the presence of adverse consequences that warrant reduction or discontinuation.
- Psychotropic and GDR support. The consultant supports the facility's efforts to justify psychotropic use and to attempt gradual dose reduction unless clinically contraindicated, with the rationale documented.
- Antibiotic stewardship input. Phase 3 reinforced infection-prevention and antibiotic stewardship programs, and pharmacy is a natural contributor to appropriate-use review.
How clinical criteria fit the requirement
CMS expects clinically sound review, and consultant pharmacists commonly lean on established criteria sets to structure it. These are tools that inform professional judgment — not automatic directives for any individual resident.
- AGS Beers Criteria. The American Geriatrics Society Beers Criteria flag medications that are potentially inappropriate in older adults and drug–disease and drug–drug interactions that merit scrutiny. The criteria are updated periodically; use the current version.
- STOPP/START. These screening tools help identify potentially inappropriate prescribing (STOPP) and potential prescribing omissions (START) in older adults.
- Anticholinergic burden (ACB). Cumulative anticholinergic exposure is a well-recognized contributor to cognitive and functional risk, and summarizing it across the regimen supports the unnecessary-drug conversation.
- ASCP practice standards. American Society of Consultant Pharmacists (ASCP) guidance frames how consultant pharmacists carry out and document regimen review in long-term care.
None of these criteria override the prescriber or the consultant's assessment of the individual resident. The consultant pharmacist evaluates whether a flag actually applies given diagnosis, goals of care, tolerability, and monitoring — and documents that reasoning.
Building a survey-ready pharmacy process
The gap most facilities discover at survey is not clinical — it is evidentiary. The recommendation was sound, but the trail connecting finding to communication to physician response is incomplete. Use these steps to close that gap.
- Standardize the review. Apply a consistent framework across every chart so findings are comparable and defensible, rather than dependent on which reviewer looked that month.
- Separate the finding from the disposition. Record the pharmacist's irregularity, the recommendation, and — as a distinct step — the physician's response and the DON's awareness.
- Track GDR attempts and contraindications. For psychotropics, capture each reduction attempt or the clinical rationale for not attempting one, so the record reflects an active process.
- Keep an append-only trail. An audit trail that cannot be silently edited protects both the pharmacist and the facility when a surveyor asks who signed what, and when.
- Close the loop on time. Turnaround on reporting and response is itself part of the expectation; a fast, documented handoff reduces open-recommendation risk.
If you operate across multiple buildings, standardization also protects your consultants' time. Consistent output means a director can review across facilities without relearning each reviewer's shorthand. Learn how this maps to long-term care workflows on our SNF solution page.
Common pitfalls that draw citations
Most avoidable findings cluster around a handful of patterns. Watch for missing indication or duration justification on high-risk drug classes, psychotropic use without a documented GDR attempt or a documented reason to defer one, and monitoring parameters that are ordered but not followed up. Another frequent gap is a recommendation that was communicated verbally but never captured in a way a surveyor can reconstruct months later.
The fix is rarely more clinical knowledge — your consultants already have that. It is a repeatable system that captures the reasoning and the response every time, without depending on memory or a stack of paper faxes.
Verify against the authority
CMS requirements, F-tag language, and the clinical criteria above are all updated over time. Before you finalize policy, confirm current details in the CMS State Operations Manual and the long-term care regulations at CMS.gov and eCFR, and use the current published editions of Beers, STOPP/START, and ASCP guidance. This article is general professional education, not legal, billing, or patient-specific clinical advice.
How WeConsultRx helps
WeConsultRx delivers AI-assisted SNF chart review with codified ASCP, Beers, and STOPP/START rule packs, so each medication regimen review runs through a consistent, criteria-informed process and lands as a finding your consultant confirms and signs. The result is faster review, clearer irregularity reporting to the physician and DON, and an append-only audit trail built for survey — the pharmacist keeps clinical judgment, and the platform keeps the evidence. Explore the clinical engine and report features or request a demo to see it against your own workflow.